Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10043806HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS10040643HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS10040644HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS10057548HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS10057463HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS10057464HBVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS30009917HIVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS30013803HIVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS30009918HIVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TVIS30013804HIVENSG00000198947.18protein_codingDMDNoNo1756A0A0S2Z3B5
A0A0S2Z3J7
A1L0U9
A7E212
P11532
Q16484
Q4G0X0
TCGA Plot Options
Drug Information
GeneDMD
DrugBank IDDB15593
Drug NameGolodirsen
Target IDBE0009794
UniProt IDP11532
Regulation Typeinducer
PubMed IDs29301272; 24554202; 30171533; 31576784
CitationsAslesh T, Maruyama R, Yokota T: Skipping Multiple Exons to Treat DMD-Promises and Challenges. Biomedicines. 2018 Jan 2;6(1). pii: biomedicines6010001. doi: 10.3390/biomedicines6010001.@@Kinter J, Sinnreich M: Molecular targets to treat muscular dystrophies. Swiss Med Wkly. 2014 Feb 19;144:w13916. doi: 10.4414/smw.2014.13916.@@Rodrigues M, Yokota T: An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases. Methods Mol Biol. 2018;1828:31-55. doi: 10.1007/978-1-4939-8651-4_2.@@Hwang J, Yokota T: Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies. Expert Rev Mol Med. 2019 Oct 2;21:e5. doi: 10.1017/erm.2019.5.
GroupsApproved
Direct Classification
SMILES
Pathways
PharmGKB
ChEMBL